Opexa Therapeutics Inc. (NASDAQ:OPXA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Saturday. According to Zacks, “Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy […]